Modernizing Medicine stock
Private-market facts for current and former Modernizing Medicine employees researching their stock.
Overview
Modernizing Medicine provides specialty-specific electronic health record systems and practice management solutions for medical specialties like dermatology and ophthalmology.
Selling Modernizing Medicine shares
Why shareholders consider selling
Shareholders in Modernizing Medicine may explore liquidity for a number of reasons — diversifying a concentrated position, funding a personal financial goal, or simply reducing exposure to a single private holding. As a private company, Modernizing Medicine does not trade on a public exchange, meaning employees and early shareholders cannot simply sell through a brokerage. Extended private timelines can leave shareholders waiting years for an exit event, which is why some choose to explore secondary-market options.
Can you sell Modernizing Medicine stock?
Whether a shareholder can sell typically depends on what they hold and how it was acquired. Vested and exercised shares are generally more straightforward than unexercised options or unvested RSUs. Most private companies, including those in the Healthcare & Biotech sector, impose transfer restrictions such as rights of first refusal or board approval requirements. The specific terms governing Modernizing Medicine shares would be outlined in the holder's equity agreement or the company's governing documents.
What affects the value of Modernizing Medicine shares?
The price a buyer is willing to pay for private shares is shaped by several factors: overall demand for the stock, the company's financial performance, broader Healthcare & Biotech market conditions, and any recent private-market transaction activity. Data points such as the company's Growth Equity round can help frame expectations, though they do not guarantee a transaction price.
What should holders check before selling
- The type of security held (common shares, preferred, options, RSUs)
- Whether the equity is fully vested and, for options, whether it has been exercised
- Any transfer restrictions, lock-up provisions, or company approval requirements
- Estimated net proceeds after applicable taxes and transaction fees
- Whether partial liquidity — selling a portion rather than the full position — may be a better fit
Tools for Modernizing Medicine shareholders
Exploring equity in Modernizing Medicine often raises questions about taxes, exercise timing, valuation, and exit outcomes. These tools can help you model different decisions using your own assumptions.
Latest funding round
Modernizing Medicine most recently raised a Growth Equity round . Total funding raised to date is approximately $319M.
Lead investors in this round include Warburg Pincus.
Founders & company background
Modernizing Medicine was founded in 2010 by Daniel Cane, Michael Sherling and is headquartered in Boca Raton, FL.
Investors
Industry
Similar private companies
Frequently asked questions
- Is Modernizing Medicine still a private company?
- Yes, Modernizing Medicine is currently a private company.
- What is Modernizing Medicine's latest funding round?
- Modernizing Medicine's most recent known round is Growth Equity.
- What is Modernizing Medicine's valuation?
- Modernizing Medicine's valuation has not been publicly disclosed.
- Who are the investors in Modernizing Medicine?
- Notable investors include Warburg Pincus.
- Can I sell my Modernizing Medicine stock?
- Private company shares can sometimes be sold on secondary markets. Speaking with a specialist who understands Modernizing Medicine stock can help you evaluate your options.
Related pages
Last verified: 2026-04-13 · Modernizing Medicine data compiled from funding disclosures, investor announcements, corporate filings, and public records.
Information on this page is compiled from publicly available sources and may be outdated or incomplete. This is not investment advice. Consult a qualified advisor before making financial decisions.